NL-OMON27925暂停不适用
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrence
VALT oncology0 个研究点目标入组 864 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 发起方
- 入组人数
- 864
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age >= 18 years
- •2. Patients with NSCLC, pT2N0, pT1N1, pT2N1, pT3N0 and pT3N1
排除标准
- •1. Patients with incomplete or inadequate pulmonary resections. incomplete preoperative or intraoperative staging, wedge or segmental resection.
- •2. Prior chemotherapy or radical radiotherapy.
研究者
相似试验
招募中
不适用
A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT 8Bon-small-cell lung cancerNL-OMON24423MCGHanzeplein 19700 RB Groningen600
进行中（未招募）
不适用
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A - NVALT-8AThis is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a non-inferiority design.EUCTR2007-002644-21-NLMCG
已完成
3 期
A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT- 8B.10038666lung cancerNon-small cell lung cancerNL-OMON35584niversitair Medisch Centrum Groningen600
尚未招募
3 期
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrence: NVALT-8AlungcancerNon-smal cell lung cancer10038666NL-OMON34015niversitair Medisch Centrum Groningen864
进行中（未招募）
不适用
A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVALT-8B - NVALT-8BThis is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadroparin for 16 weeks in order to improve the recurrence-free survival rate in these patients.EUCTR2007-002608-16-NLMCG